AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2022
Categories |
Back to Blog
The growing demand for Generic medicines has created a global marketplace for these suppliers. However, regulating and cost-saving opportunities for generic medicine suppliers are still issues of concern. In this article, we will explore the Regulation of generic medicine suppliers and the opportunities available in the Global marketplace. We will also discuss some of the best practices for suppliers of these medicines. Listed below are some of these tips: Generic medicines The Orphan Drug Act was passed in 1983, and it provided incentives to drug makers to produce and market generic medicines. The Hatch-Waxman Act of 1984 was passed in response to the AIDS crisis, and it provides monetary and marketing incentives to generic medicine suppliers. The goal of the Act is to make medicines available to people without sacrificing quality. In addition, the Act aims to save Americans money on medicine bills. The AMA supports these efforts by encouraging high-level awareness of generic medicines, promoting their use, and reducing actual conflicts of interest . The global trade in Generic Medicine involves many countries, including India. India is one of these countries, and its Generic Medicine distributors have a significant market potential in the global marketplace. But finding a reliable distributors is not as easy as comparing price lists. It involves other factors, such as the value for money, quality, reliability, and previous trade history. Connect2India is a marketplace for finding Generic Medicine distributors in India and helps buyers connect with reliable distributors. Cost-saving opportunities for generic medicine distributors As the market for generic drugs continues to grow, manufacturers are focusing on ways to reduce their COGS. In the U.S. alone, patent expirations totaled $8 billion in 2019 alone, with an even larger number expected in the next five years. But this growth comes with significant challenges, including unsteady economics and disruptions in the supply chain. For example, most generics players outsource manufacturing to cheaper markets, such as India. But this move is fraught with quality concerns and other risks. To be able to make strategic decisions based on cost data, generic drug manufacturers should use artificial intelligence and digital technologies to allocate costs to individual SKUs. This data can help commercial and technical operations optimize services, outsource products, and price products more accurately. This data is critical for evaluating the cost of each product. However, it must not be used to replace a physician's decision. While this technology can greatly reduce costs for manufacturers, it doesn't address other key issues . Regulation of generic medicine distributors The FDA has made it a priority to regulate the generic drug market. The agency has developed the Drug Competition Action Plan, which is intended to promote robust generic competition while maintaining the scientific rigor of the generic drug program. The plan is aimed at ensuring that consumers receive safe and effective generic drugs. The plan requires that generic drug manufacturers purchase samples of brand-name medicines and demonstrate bioequivalence with the brand-name product. The US health regulators have begun to implement small-batch tests of imported drugs more regularly. White says this is a "start" but must be increased until in-person foreign inspections are available. In the meantime, the affordability of generics remains a significant factor in their popularity. The manufacturers often try to undercut the competition with the lowest prices. But this is not sustainable in the long term. In the US, the government must provide incentives to pharmaceutical companies that invest in research and development. Global marketplace for generic medicine distributors The Asia-Pacific region is expected to grow quickly over the next decade, with emphasis on increasing the number of generic medicines and sourcing from non-traditional sources. While Japan, for example, has a low rate of use of generic medicines, that rate has recently increased to 68 percent. However, Japan's economy has taken a hit from the "value-based" healthcare reform that is driving down top-line pricing. After years of price declines, the global generic sector is at full production, but it is also going through significant restructuring. While generic manufacturers rationally focus on the most profitable products, they are stopping production of cheaper generics. Meanwhile, many firms are looking to offset the excess capacity created by pruning less profitable products. Ultimately, this will have a significant impact on the supply chain. In light of this, global generic suppliers must look at their business models and invest in their capabilities.
0 Comments
Read More
Leave a Reply. |